• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Physiology >Corticosteroids increase glutamine utilization in human splanchnic bed
【24h】

Corticosteroids increase glutamine utilization in human splanchnic bed

机译：皮质类固醇增加人体内脏床中谷氨酰胺的利用率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

First published December 27, 2007; doi:10.1152/ajpgi.00461.2007.-Glutamine is the most abundant amino acid in the body and is extensively taken up in gut and liver in healthy humans. To determine whether glucocorticosteroids alter splanchnic glutamine metabolism, the effect of prednisone was assessed in healthy volunteers using isotope tracer methods. Two groups of healthy adults received 5-h intravenous infusions of l-[1-14C]leucine and l-[~2H_5]glutamine, along with q. 20 min oral sips of tracer doses of L-[l~(-1)3C]glutamine in the fasting state, either J) at baseline (control group; n - 6) or 2) after a 6-day course of 0.8 mg-kg~(-1)day~(-1) prednisone (prednisone group; n - 8). Leucine and glutamine appearance rates (Ra) were determined from plasma [l~(-1)4C]ketoisocaproate and [~2H_5]glutamine, respectively, and leucine and glutamine oxidation from breath ,~(14)CO_2 and ~(13)CO_2, respectively. Splanchnic glutamine extraction was estimated by the fraction of orally administered [~(13)C]glutamine that failed to appear into systemic blood. Prednisone treatment 7) did not affect leucine Ra or leucine oxidation; 2) increased plasma glutamine Ra, mostly owing to enhanced glutamine de novo synthesis (medians +- interquartiles, 412 +-61 vs. 280 +- 190 njnol-kg~(-1) h~(-1) P = 0.003); and 3) increased the fraction of orally administered glutamine undergoing extraction in the splanchnic territory (means +- SE 64 +- 6 vs. 42 +- 12%, P < 0.05), without any change in the fraction of glutamine oxidized (means +-SE, 75 +- 4 vs. 77 +- 4%, not significant). We conclude that high-dose glucocorticosteroids increase in splanchnic bed the glutamine requirements. The role of such changes in patients receiving chronic corticoid treatment for inflammatory diseases or suffering from severe illness remains to be determined.
机译：首次发布于2007年12月27日; doi：10.1152 / ajpgi.00461.2007.-谷氨酰胺是人体中最丰富的氨基酸，在健康人的肠道和肝脏中广泛摄取。为了确定糖皮质激素是否改变内脏谷氨酰胺代谢，使用同位素示踪法在健康志愿者中评估了泼尼松的作用。两组健康的成年人在接受5-h静脉注射1- [1-14C]亮氨酸和1- [〜2H_5]谷氨酰胺以及q的同时输注。禁食状态下的L- [l〜（-1）3C]谷氨酰胺示踪剂量的20分钟口服，在0.8天的6天疗程后于基线（J）（对照组; n-6）或2） -kg〜（-1）day〜（-1）泼尼松（泼尼松组; n-8）。分别从血浆[l〜（-1）4C]酮异己酸和[〜2H_5]谷氨酰胺，以及来自呼吸，〜（14）CO_2和〜（13）CO_2的亮氨酸和谷氨酰胺氧化来测定亮氨酸和谷氨酰胺的出现率（Ra）。 ， 分别。内脏谷氨酰胺提取是通过口服给药的[〜（13）C]谷氨酰胺未能出现在全身血液中的比例来估算的。泼尼松治疗7）不影响亮氨酸Ra或亮氨酸氧化; 2）血浆谷氨酰胺Ra升高，主要归因于谷氨酰胺从头合成的增强（中位数+-四分位数，412 + -61对280 +-190 njnol-kg〜（-1）h〜（-1）P = 0.003）;和3）增加内脏区域中口服提取的谷氨酰胺的比例（平均值+-SE 64 +-6 vs. 42 +-12％，P <0.05），而谷氨酰胺氧化的比例没有变化（平均值+ -SE，分别为75 +-4和77 +-4％，不显着）。我们得出的结论是，在内脏床上大剂量的糖皮质激素类固醇会增加谷氨酰胺的需求量。这种变化在接受慢性皮质类固醇激素治疗炎症性疾病或患有严重疾病的患者中的作用尚待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号